0.5651 USD
-0.07 (-11.7%)
0.5756 USD
+0.01 (+1.86%)
ChartMill assigns a Buy % Consensus number of 83% to MREO. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 2.12. This target is 276.03% above the current price.
- MREO was analyzed by 14 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MREO.
- In the last month the buy percentage fell by 5 points. So the trust of analysts is decreasing.
- MREO was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-16 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-13 | Needham | Maintains | Buy -> Buy |
| 2025-12-30 | Jefferies | Downgrade | Buy -> Hold |
| 2025-12-29 | LifeSci Capital | Downgrade | Outperform -> Market Perform |
| 2025-12-29 | BTIG | Maintains | Buy -> Buy |
| 2025-12-22 | Needham | Reiterate | Buy -> Buy |
| 2025-12-18 | BTIG | Reiterate | Buy -> Buy |
| 2025-08-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-10 | Needham | Maintains | Buy -> Buy |
| 2025-05-13 | Needham | Reiterate | Buy -> Buy |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-03-27 | JP Morgan | Initiate | Overweight |
| 2025-03-26 | Needham | Reiterate | Buy -> Buy |
| 2025-03-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2024-12-24 | LifeSci Capital | Initiate | Outperform |
| 2024-12-06 | Jefferies | Initiate | Buy |
| 2024-11-12 | Needham | Reiterate | Buy -> Buy |
| 2024-10-01 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-13 | Needham | Reiterate | Buy -> Buy |
| 2024-07-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-06-13 | Baird | Initiate | Outperform |
| 2024-06-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-12 | Needham | Maintains | Buy -> Buy |
| 2024-05-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-16 | Needham | Reiterate | Buy -> Buy |
| 2024-04-10 | Needham | Reiterate | Buy -> Buy |
| 2024-03-28 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What is the average price target for MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
14 analysts have analysed MREO and the average price target is 2.12 USD. This implies a price increase of 276.03% is expected in the next year compared to the current price of 0.5651.
How do analysts rate MEREO BIOPHARMA GROUP PL-ADR (MREO)?
The consensus rating for MEREO BIOPHARMA GROUP PL-ADR (MREO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for MEREO BIOPHARMA GROUP PL-ADR stock?
The number of analysts covering MEREO BIOPHARMA GROUP PL-ADR (MREO) is 14.